Single and multiple dose multistem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: A phase 1 trial

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 4, 2015, Pages 720-728

  Maziarz, Richard T ^a   Devos, Timothy ^b   Bachier, Carlos R ^c   Goldstein, Steven C ^d,i   Leis, Jose F ^e   Devine, Steven M ^f   Meyers, Gabrielle ^a   Gajewski, James L ^a   Maertens, Johan ^b   Deans, Robert J ^g   Van't Hof, Wouter ^g   Lazarus, Hillard M ^h  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c TEXAS TRANSPLANT INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MAYO CLINIC HOSPITAL   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g ATHERSYS INC   (United States)

^h UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

ⁱ UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Graft versus host disease; Mesenchymal stromal cells; Multipotent adult progenitor cells; Myeloablative allogeneic hematopoietic cell transplantation; Phase 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; HLA ANTIBODY; MELPHALAN; METHOTREXATE; TACROLIMUS;

ABNORMAL LABORATORY RESULT; ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; KIDNEY FAILURE; LEUKEMIA RELAPSE; LIVER FUNCTION TEST; LUNG INFECTION; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPOTENT ADULT PROGENITOR CELL; MYCOSIS; MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION; MYELOABLATIVE CONDITIONING; NAUSEA AND VOMITING; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PROTOZOAL INFECTION; RESPIRATORY FAILURE; STEM CELL; THROMBOCYTE; THROMBOCYTE TRANSFUSION; VIRUS INFECTION; WHOLE BODY RADIATION; ACUTE DISEASE; ADOLESCENT; ADULT STEM CELL; AGED; ALLOGRAFT; CLINICAL TRIAL; CONTROLLED STUDY; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; MIDDLE AGED; MULTIPOTENT STEM CELL; RANDOMIZED CONTROLLED TRIAL; TRANSPLANTATION;

ACUTE DISEASE; ADOLESCENT; ADULT; ADULT STEM CELLS; AGED; ALLOGRAFTS; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPOTENT STEM CELLS;

EID: 84924273627     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.12.025     Document Type: Article

References (35)

1. Lazarus H.M., Haynesworth S.E., Gerson S.L., et al. Exvivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995, 16:557-564.
2. Le Blanc K., Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. JIntern Med 2007, 262:509-525.
3. Koç O.N., Gerson S.L., Cooper B.W., et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. JClin Oncol 2000, 18:307-316.
4. Lazarus H.M., Koç O.N., Devine S.M., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005, 11:389-398.
5. Le Blanc K., Samuelsson H., Gustafsson B., et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007, 21:1733-1738.
6. Ringden O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
7. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
8. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
9. Kebriaei P., Isola L., Bahceci E., et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:804-811.
10. Martin P.J. Prochymal® improves response rates in patients with steroid refractory acute graft-versus-host disease involving the liver and gut: results of a randomized, placebo-controlled, multicentre phase III trial in GvHD. Bone Marrow Transplant 2010, 45(S1):77.
11. Szabolcs P., Visani G., Locatelli F., et al. Treatment of steroid-refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients: results of the pediatric subset in a phase III randomized, placebo-controlled study (abstract). Biol Blood Marrow Transplant 2012, 16:S298.
12. Jiang Y., Jahagirdar B.N., Reinhardt R.L., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41-49.
13. Reading J.L., Yang J.H.M., Sabbah S., et al. Clinical-grade multipotent adult progenitor cells durably control pathogenic T cell responses in human models of transplantation and autoimmunity. JImmunol 2013, 190:4542-4552.
14. Jacobs S.A., Pinxteren J., Roobrouck V.D., et al. Human multipotent adult progenitor cells are non-immunogenic and exert potent immunomodulatory effects on alloreactive T cell responses. Cell Transplant 2013, 22:1915-1928.
15. Jacobs S.A., Roobrouck V.D., Verfaillie C.M., Van Gool S.W. Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells. Immunol Cell Biol 2013, 91:32-39.
16. Boozer S., Lehman N., Lakshmipathy U., et al. Global characterization and genomic stability of MultiStem®, a multipotent adult progenitor cell. JStem Cells 2009, 4:17-28.
17. Kovacsovics-Bankowski M., Mauch K., Raber A., et al. Pre-clinical safety testing supporting clinical use of allogeneic multipotent adult progenitor cells. Cytotherapy 2008, 10:730-742.
18. Kovacsovics-Bankowski M., Streeter P.R., Mauch K.A., et al. Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease. Cell Immunol 2009, 255:55-60.
19. Metheny L.L., Eid S., Keller M., et al. Human multipotent adult progenitor cells effectively modulate alloreactivity after bone marrow transplantation reducing GVHD while preserving graft-versus-leukemia activity. Biol Blood Marrow Transplant 2012, 18:S368-S369.
20. Popp F.C., Fillenberg B., Eggenhofer E., et al. Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplanatation - a phase I study (MISOT-I). JTransl Med 2011, 9:124.
21. Vaes B., Van't Hof W., Deans R., Pinxteren J. Application of MultiStem(®) allogeneic cells for immunomodulatory therapy: clinical progress and pre-clinical challenges in prophylaxis for graft versus host disease. Front Immunol 2012, 3:345.
22. Bearman S.I., Appelbaum F.R., Buckner C.D., et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. JClin Oncol 1988, 6:1562-1568.
23. Thall P.F., Lee S.J. Practical model-based dose-finding in phase I clinical trials: methods based on toxicity. Int J Gynecol Cancer 2003, 13:251-261.
24. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96:2062-2068.
25. Potter V., Moore J. Randomised trials of graft versus host disease prophylaxis in haemopoietic stem cell transplantation. Rev Recent Clin Trials 2008, 3:130-138.
26. Cutler C., Logan B.R., Nakamura R., et al. Tacrolimus/sirolimus vs. tacrolimus/methotrexate for graft-vs.-host disease prophylaxis after HLA-matched, related donor hematopoietic stem cell transplantation: results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. Blood 2012, 120(S1):739.
27. Anasetti C., Logan B.R., Lee S.J., et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. NEngl J Med 2012, 367:1487-1496.
28. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998, 92:2303-2314.
29. Eapen M., Logan B.R., Confer D.L., et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007, 13:1461-1468.
30. Ochs L., Shu X.O., Miller J., et al. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood 1995, 86:3979-3986.
31. Junghanss C., Marr K.A., Carter R.A., et al. Incidence and outcome ofbacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002, 8:512-520.
32. Luznik L., Bolaños-Meade J., Zahurak M., et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010, 115:3224-3230.
33. Luznik L., Jones R.J., Fuchs E.J. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol 2010, 17:493-499.
34. National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Available at: http://ctep.cancer.gov/forms/CTCAEv3.pdf.
35. Blood and Marrow Transplant Clinical Trials Network Technical Manual of Procedures, Version 2, dated September 16, 2005. Available at: http://web.emmes.com/study/bmt2/public/MOP/BMT_CTN_Technical_MOP_ver_2.0.pdf.